Abstract
Smoking pack-years are associated with a sharper increase in the risk of small cell lung cancer (SCLC). Statins are recognized as powerful anti-inflammatory agents, which reduce the risk of lung cancer in chronic obstructive pulmonary disease. Previously, we found a potential survival benefit of irinotecan and cisplatin (IP) in combination with simvastatin in heavy-smoking extensive disease (ED)-SCLC patients. This study evaluated whether a combination of simvastatin with IP improve clinical outcomes of ever-smoker ED-SCLC patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
